Hostname: page-component-669899f699-b58lm Total loading time: 0 Render date: 2025-04-27T05:05:30.981Z Has data issue: false hasContentIssue false
  • English
  • Français

Nanostructured lipid carrier delivering chlorins e6 as in situ dendritic cell vaccine for immunotherapy of gastric cancer

Published online by Cambridge University Press:  03 November 2020

Mao Mao ,
Senfeng Liu ,
Yiming Zhou ,
Gonghe Wang ,
Jianping Deng  and
Lei Tian
Mao Mao
Affiliation:
Department of Gastric Gland Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi530021, China
Senfeng Liu
Affiliation:
Department of Gastric Gland Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi530021, China
Yiming Zhou
Affiliation:
Department of Gastric Gland Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi530021, China
Gonghe Wang
Affiliation:
Department of Gastric Gland Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi530021, China
Jianping Deng
Affiliation:
Department of Gastric Gland Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi530021, China
Lei Tian*
Affiliation:
Department of Gastric Gland Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi530021, China
*
a)Address all correspondence to this author. e-mail: [email protected]
Get access

Abstract

The recent scientific progress has shown the promising effect of the vaccine in immunotherapy of cancer, which relies on the antigen processing/presentation capability of dendritic cells (DCs). As a result, cancer vaccines targeting DC, which also named as DC vaccine, was a hot-spot in vaccine development. Herein, a nanostructured lipid carrier (NLC) was employed to load chlorin e6 (Ce6) to serve as a potential in situ DC vaccine (NLC/Ce6) for effective immunotherapy of gastric cancer. Taking advantage of the photodynamic effect of Ce6 to generate reactive oxygen species (ROS) under laser irradiation, the NLC/Ce6 was able to trigger cell death and expose tumor-associated antigen (TAA). Moreover, mimicking the natural inflammatory response, the ROS can also recruit the DC for the effective processing/presentation of the in situ exposed TAA. As expected, we observed strong capability DC vaccination efficacy of this platform to effectively inhibit the growth of both primary and distant gastric tumors.

Type
Article
Information
Journal of Materials Research , Volume 35 , Issue 23-24 , 14 December 2020 , pp. 3257 - 3264
Check for updates
Copyright
Copyright © The Author(s), 2020, published on behalf of Materials Research Society by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

b)

These authors contributed equally to this work.

References

Neek, M., Kim, T.I., and Wang, S.-W.: Protein-based nanoparticles in cancer vaccine development. Nanomedicine—Nanotechnol. 15, 164 (2019).Google ScholarPubMed
Saxena, M. and Bhardwaj, N.: Re-emergence of dendritic cell vaccines for cancer treatment. Trends Cancer 4, 119 (2018).CrossRefGoogle ScholarPubMed
Mastelic-Gavillet, B., Balint, K., Boudousquie, C., Gannon, P.O., and Kandalaft, L.E.: Personalized dendritic cell vaccines—Recent breakthroughs and encouraging clinical results. Front. Immunol. 10, 766 (2019).CrossRefGoogle ScholarPubMed
Mougel, A., Terme, M., and Tanchot, C.: Therapeutic cancer vaccine and combinations with antiangiogenic therapies and immune checkpoint blockade. Front. Immunol. 10, 467 (2019).CrossRefGoogle ScholarPubMed
Dobrovolskienė, N., Pašukonienė, V., Darinskas, A., Kraśko, J.A., Žilionytė, K., Mlynska, A., Gudlevičienė, Ž, Mišeikytė-Kaubrienė, E., Schijns, V., and Lubitz, W.: Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines. Vaccine 36, 4171 (2018).CrossRefGoogle ScholarPubMed
Restifo, N.P., Dudley, M.E., and Rosenberg, S.A.: Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat. Rev. Immunol. 12, 269 (2012).CrossRefGoogle ScholarPubMed
Palucka, K., and Banchereau, J.: Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12, 265 (2012).CrossRefGoogle ScholarPubMed
Wang, C., Yu, F., Liu, X., Chen, S., Wu, R., Zhao, R., Hu, F., and Yuan, H.: Cancer-specific therapy by artificial modulation of intracellular calcium concentration. Adv. Healthcare Mater. 8, 1900501 (2019).CrossRefGoogle ScholarPubMed
Yang, X., Yu, T., Zeng, Y., Lian, K., Zhou, X., Li, S., Qiu, G., Jin, X., Yuan, H., and Hu, F.: Tumor-draining lymph node targeting chitosan micelles as antigen-capturing adjuvants for personalized immunotherapy. Carbohydr. Polym. 240, 116270 (2020).CrossRefGoogle ScholarPubMed
Wang, C., Chen, S., Bao, L., Liu, X., Hu, F., and Yuan, H.: Size-controlled preparation and behavior study of phospholipid–calcium carbonate hybrid nanoparticles. Int. J. Nanomed. 15, 4049 (2020).CrossRefGoogle ScholarPubMed
Li, M., Liu, Y., Chen, J., Liu, T., Gu, Z., Zhang, J., Gu, X., Teng, G., Yang, F., and Gu, N.: Platelet bio-nanobubbles as microvascular recanalization nanoformulation for acute ischemic stroke lesion theranostics. Theranostics 8, 4870 (2018).CrossRefGoogle ScholarPubMed
Wen, R., Umeano, A.C., Kou, Y., Xu, J., and Farooqi, A.A.: Nanoparticle systems for cancer vaccine. Nanomedicine 14, 627 (2019).CrossRefGoogle ScholarPubMed
Meka, R.R., Mukherjee, S., Patra, C.R., and Chaudhuri, A.: Shikimoyl-ligand decorated gold nanoparticles for use in ex vivo engineered dendritic cell based DNA vaccination. Nanoscale 11, 7931 (2019).CrossRefGoogle ScholarPubMed
Dings, R.P.M., Cannon, M., and Vang, K.B.: Design of gold nanoparticles in dendritic cell-based vaccines. Part. Part. Syst. Charact. 35, 1800109 (2018).CrossRefGoogle Scholar
Zhao, X., Tang, D., Yang, T., and Wang, C.: Facile preparation of biocompatible nanostructured lipid carrier with ultra-small size as a tumor-penetration delivery system. Colloids Surf., B 170, 355 (2018).CrossRefGoogle ScholarPubMed
Tapeinos, C., Marino, A., Battaglini, M., Migliorin, S., Brescia, R., Scarpellini, A., De Julián Fernández, C., Prato, M., Drago, F., and Ciofani, G.: Stimuli-responsive lipid-based magnetic nanovectors increase apoptosis in glioblastoma cells through synergic intracellular hyperthermia and chemotherapy. Nanoscale 11, 72 (2019).CrossRefGoogle Scholar
Tambe, P., Kumar, P., Paknikar, K.M., and Gajbhiye, V.: Decapeptide functionalized targeted mesoporous silica nanoparticles with doxorubicin exhibit enhanced apoptotic effect in breast and prostate cancer cells. Int. J. Nanomed. 13, 7669 (2018).CrossRefGoogle ScholarPubMed
Sun, X., Sun, J., Lv, J., Dong, B., Liu, M., Liu, J., Sun, L., Zhang, G., Zhang, L., and Huang, G.: Ce6-C6-TPZ co-loaded albumin nanoparticles for synergistic combined PDT-chemotherapy of cancer. J. Mater. Chem. B 7, 5797 (2019).CrossRefGoogle ScholarPubMed
Jin, G., He, R., Liu, Q., Lin, M., Dong, Y., Li, K., Tang, B.Z., Liu, B., and Xu, F.: Near-infrared light-regulated cancer theranostic nanoplatform based on aggregation-induced emission luminogen encapsulated upconversion nanoparticles. Theranostics 9, 246 (2019).CrossRefGoogle ScholarPubMed
Yang, J., Teng, Y., Fu, Y., and Zhang, C.: Chlorins e6 loaded silica nanoparticles coated with gastric cancer cell membrane for tumor specific photodynamic therapy of gastric cancer. Int. J. Nanomed. 14, 5061 (2019).CrossRefGoogle ScholarPubMed
He, C., Duan, X., Guo, N., Chan, C., Poon, C., Weichselbaum, R.R., and Lin, W.: Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nat. Commun. 7, 1 (2016).CrossRefGoogle ScholarPubMed
Ma, S., Zhou, J., Zhang, Y., Yang, B., He, Y., Tian, C., Xu, X., and Gu, Z.J.A.A.M.: An oxygen self-sufficient fluorinated nanoplatform for relieved tumor hypoxia and enhanced photodynamic therapy of cancers. ACS Appl. Mater. Interfaces 11(8), 7731–7742.CrossRefGoogle Scholar
He, H., Zhu, R., Sun, W., Cai, K., Chen, Y., and Yin, L.: Selective cancer treatment via photodynamic sensitization of hypoxia-responsive drug delivery. Nanoscale 10, 2856 (2018).CrossRefGoogle ScholarPubMed
Hu, R., Zheng, H., Cao, J., Davoudi, Z., and Wang, Q.: Synthesis and in vitro characterization of carboxymethyl chitosan–CBA–doxorubicin conjugate nanoparticles as pH-sensitive drug delivery systems. J. Biomed. Nanotechnol. 13, 1097 (2017).CrossRefGoogle ScholarPubMed
Gao, F., Zhang, J.M., Fu, C.M., Xie, X.M., Peng, F., You, J.S., Tang, H.L., Wang, Z.Y., Li, P., and Chen, J.P.: iRGD-modified lipid–polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability. Int. J. Nanomed. 12, 4147 (2017).CrossRefGoogle ScholarPubMed
Brillault, L., Jutras, P.V., Dashti, N., Thuenemann, E.C., Morgan, G., Lomonossoff, G.P., Landsberg, M.J., and Sainsbury, F.: Engineering recombinant virus-like nanoparticles from plants for cellular delivery. ACS Nano. 11, 3476 (2017).CrossRefGoogle ScholarPubMed
Negi, L.M., Talegaonkar, S., Jaggi, M., and Verma, A.K.: Hyaluronated imatinib liposomes with hybrid approach to target CD44 and P-gp overexpressing MDR cancer: an in-vitro, in-vivo and mechanistic investigation. J. Drug Target. 27, 183 (2019).CrossRefGoogle ScholarPubMed
Wang, C., Wang, Z., Zhao, X., Yu, F., Quan, Y., Cheng, Y., and Yuan, H.: DOX loaded aggregation-induced emission active polymeric nanoparticles as a fluorescence resonance energy transfer traceable drug delivery system for self-indicating cancer therapy. Acta Biomater. 85, 218 (2019).CrossRefGoogle ScholarPubMed
Ni, J., Sun, Y., Song, J., Zhao, Y., Gao, Q., and Li, X.: Artificial cell-mediated photodynamic therapy enhanced anticancer efficacy through combination of tumor disruption and immune response stimulation. ACS Omega 4, 12727 (2019).CrossRefGoogle ScholarPubMed
Ding, X., Xu, X., Zhao, Y., Zhang, L., Yu, Y., Huang, F., Yin, D., and Huang, H.: Tumor targeted nanostructured lipid carrier co-delivering paclitaxel and indocyanine green for laser triggered synergetic therapy of cancer. RSC Adv. 7, 35086 (2017).CrossRefGoogle Scholar
Wang, C., Han, M., Liu, X., Chen, S., Hu, F., Sun, J., and Yuan, H.: Mitoxantrone-preloaded water-responsive phospholipid-amorphous calcium carbonate hybrid nanoparticles for targeted and effective cancer therapy. Int. J. Nanomed. 14, 1503 (2019).CrossRefGoogle ScholarPubMed
Zheng, X., Zhang, F., Zhao, Y., Zhang, J., Dawulieti, J., Pan, Y., Cui, L., Sun, M., Shao, D., and Li, M.: Self-assembled dual fluorescence nanoparticles for CD44-targeted delivery of anti-miR-27a in liver cancer theranostics. Theranostics 8, 3808 (2018).CrossRefGoogle ScholarPubMed
Zhao, X., Liu, Y., Yu, Y., Huang, Q., Ji, W., Li, J., and Zhao, Y.: Hierarchically porous composite microparticles from microfluidics for controllable drug delivery. Nanoscale 10, 12595 (2018).CrossRefGoogle ScholarPubMed